Uncategorized
Eyenovia phase 2 trial shows positive results in microtherapeutic approach to dosing
Eyenovia’s topical piezo-print microtherapeutic approach to dosing has shown positive safety and efficacy results in a phase 2 study, the company announced in a press release.The EYE 102 study showed an 8% reduction in ocular side effects with the microtherapeutic approach compared with 66% with conventional topical treatment, the release said.